Optomed Q2: Soft Q2 sales raises the stakes for H2 recovery - Redeye

Redeye provides an update following Optomed’s Q2 2025 report. Sales came in below our expectations, and we had anticipated a more pronounced impact from the Aurora AEYE camera. As a result, we have made downward adjustments to our sales estimates, leading to an updated fair value range.

Länk till analysen i sin helhet: https://www.redeye.se/research/1121556/optomed-q2-soft-q2-sales-raises-the-stakes-for-h2-recovery?utm_source=finwire&utm_medium=RSS